変形性顎関節症に対するフィセチンの関節内治療効果と持続的放出への応用

Temporomandibular joint osteoarthritis (TMJOA) is characterized by progressive osteochondral degeneration, and the efficacy of current intra-articular clinical treatments remains inconsistent. Fisetin (FST) has shown therapeutic promise in osteoarthritis. In this study, an monosodium iodoacetate (MIA)-induced TMJOA rat model was used to evaluate the reparative effects of intra-articularly administered FST on condylar cartilage damage. The results demonstrated that FST exhibited a transient improvement in TMJOA-associated abnormalities in cartilage thickness, but the effect did not persist long-term. To address the pharmacokinetic limitations of FST, FST-loaded poly(lactic-co-glycolic acid) nanoparticles (FST-PNP) were prepared using a single emulsion solvent evaporation method. The nanoparticles exhibited uniform morphology and favorable sustained-release properties, which markedly extended the release duration of FST. These results indicate that a sustained-release of FST from poly(lactic-co-glycolic acid) (PLGA) nanoparticles can be a promising material for TMJOA treatment.